Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.58 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355610 | 1.00 | KMT2A (0.70) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL1355724 | 1.00 | KMT2A (0.70) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL1355612 | 1.00 | KMT2A (0.70) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL1355624 | 0.94 | KMT2A (0.74) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL1354985 | 0.94 | KMT2A (0.74) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL1356493 | 0.94 | KMT2A (0.74) | KMT2AMEN1CYP2D6SERPINE1SHBG | |
| SCHEMBL12137173 | 0.92 | KMT2A (0.70) | KMT2AMEN1CYP2D6SHBGSLC22A6 | |
| SCHEMBL8887975 | 0.90 | KMT2A (0.68) | KMT2AMEN1CYP2D6SHBGSLC22A6 | |
| SCHEMBL17941252 | 0.90 | KMT2A (0.68) | KMT2AMEN1CYP2D6SHBGSLC22A6 | |
| SCHEMBL1355728 | 0.88 | KMT2A (0.73) | KMT2AMEN1CYP2D6SERPINE1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | claimed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | claimed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | PSEN2, PSEN1, VHL | KMT2A 1383/4885MEN1 2016/4885CYP2D6 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.